Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel-group, 26-week Study Comparing the Efficacy and Safety of Indacaterol (Onbrez Breezhaler 150 μg o.d.) With Salmeterol/Fluticasone Propionate (Seretide Accuhaler 50 μg/500 μg b.i.d.) in Patients With Moderate Chronic Obstructive Pulmonary Disease

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Parallel-group, 26-week Study Comparing the Efficacy and Safety of Indacaterol (Onbrez Breezhaler 150 μg o.d.) With Salmeterol/Fluticasone Propionate (Seretide Accuhaler 50 μg/500 μg b.i.d.) in Patients With Moderate Chronic Obstructive Pulmonary Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms INSTEAD
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 30 Oct 2014 Results published in the European Respiratory Journal.
    • 30 Oct 2014 Status changed from active, no longer recruiting to completed according to the Results published in the European Respiratory Journal
    • 25 Apr 2014 Top-line results reported in a Novartis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top